Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ABX203

Other · developed by Abivax

Phase 2/3 Most advanced trial (none active)
ABVX Developer
1 Registered trials

What is ABX203?

ABX203 is an investigational drug studied in Chronic Hepatitis B.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
Abivax S.A. (ABVX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02249988 Phase 2/3 Chronic Hepatitis B Completed ABVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis B

More from Abivax

ABX196 Phase 1/2 Obefazimod Phase 3

Follow ABVX, the company behind ABX203

See ABVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABVX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.